Bio-Rad Laboratories BIO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.59B+0.3% | $2.58B+1.0% | $2.56B+0.1% | $2.55B+0.5% | $2.54B-1.0% | ||
| $1.25B+0.3% | $1.24B+1.8% | $1.22B+1.3% | $1.21B+1.9% | $1.18B-0.5% | ||
| $1.34B+0.3% | $1.34B+0.2% | $1.34B-0.9% | $1.35B-0.7% | $1.36B-1.4% | ||
| 51.9%0.0pp | 51.9%-0.4pp | 52.3%-0.6pp | 52.8%-0.7pp | 53.5%-0.2pp | ||
| $265M-3.8% | $275.6M-3.3% | $284.9M-6.5% | $304.6M+0.5% | $303M+2.4% | ||
| $847.9M+0.4% | $844.3M+2.1% | $827.3M+0.8% | $820.9M+1.6% | $807.9M-0.7% | ||
| —— | —— | $224.4M+0.4% | $223.6M-9.8% | $248M-7.8% | ||
| $49.3M+0.6% | $49M-0.2% | $49.1M+0.4% | $48.9M+0.6% | $48.6M-0.6% | ||
| $77.3M-14.4% | $90.3M+11.1% | $81.3M-10.6% | $90.9M-2.2% | $92.9M+2.9% | ||
| $222.3M-77.7% | $995.5M+218% | -$842.6M-287% | $450.1M+116% | -$2.75B-17.4% | ||
| $53.5M-77.3% | $235.6M+241% | -$166.7M-227% | $130.9M+122% | -$586.1M-17.6% | ||
| $5.81-79.0% | $27.65+214% | -$24.31-307% | $11.73+115% | -$76.20-17.2% | ||
| $1.12B+0.9% | $1.11B+393% | $224.4M+0.4% | $223.6M-9.8% | $248M-7.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Bio-Rad Laboratories's revenue?
- Bio-Rad Laboratories (BIO) generated $2.6B in revenue over the trailing twelve months, up 1.9% year over year.
- Is Bio-Rad Laboratories profitable?
- Bio-Rad Laboratories reported $168.8M in net income over the trailing twelve months, a 6.5% net margin.
- What are Bio-Rad Laboratories's profit margins?
- Gross margin is 51.9% and operating margin is 8.8%, with a 6.5% net margin.
- What is Bio-Rad Laboratories's earnings per share?
- Bio-Rad Laboratories's diluted EPS over the trailing twelve months is $5.81.
- Where does Bio-Rad Laboratories's income statement data come from?
- Every line is extracted from Bio-Rad Laboratories's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
